Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
Author:
Affiliation:
1. Department of Hematology National Cancer Center Hospital Tokyo Japan
2. Department of Pathology National Cancer Center Hospital Tokyo Japan
Publisher
Wiley
Subject
Cancer Research,Radiology Nuclear Medicine and imaging,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4062
Reference33 articles.
1. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
2. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
3. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy
4. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
5. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma;European Journal of Haematology;2024-01-03
2. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma;Blood Reviews;2024-01
3. Efficacy and Safety of Anti-PD-1/PD-L1 Antibodies in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma: A Meta-Analysis;J BIOL REG HOMEOS AG;2023
4. HK2 contributes to the proliferation, migration, and invasion of diffuse large B-cell lymphoma cells by enhancing the ERK1/2 signaling pathway;Open Life Sciences;2023-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3